MANNKIND CORP
MNKDNasdaq
$4.03
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +1.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.2B
Enterprise Value
$1.4B
P/E
—
P/S
3.4
P/B
—
EV/EBITDA
45.5
PEG
—
FCF Yield
1.1%
Dividend Yield
—
Revenue (TTM)
$360.8M
Net Income (TTM)
-$23.9M
Free Cash Flow (TTM)
$13.2M
Gross Margin
—
Operating Margin
4.1%
Net Margin
-6.6%
ROE
40.4%
ROIC
9.3%
Debt / Equity
-5.4
Net Cash
-$184.9M
Return 1Y
+3.3%
Company profile
MannKind focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
- CEO
- Michael E. Castagna
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 400
- Headquarters
- Connecticut
- Website
- mannkindcorp.com
Management & directors
- Thomson DavidEVP Genl Counsel & Secretary
- Castagna MichaelChief Executive Officer
- Marasco DominicPres, Endocrine Business Unit
- Prentiss Christopher BChief Financial Officer
- Singh Sanjay REVP Technical Operations
- Tross Stuart AChief People & Workpl Officer
- Ahuja AjayChief Medical Officer
- Blank BurkhardEVP Chief Medical Officer
- Sabella Lauren MEVP Operations
Roles derived from SEC Form 4 filings.
Earnings
MNKD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$90.2M↑ +15.1%
Diluted EPS-$0.05↓ -225.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $65.1M | $75.4M | $99.8M | $199.0M | $285.5M | $349.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$47.9M | -$47.0M | -$64.1M | $8.7M | $72.6M | $38.8M |
| Net income | -$57.2M | -$80.9M | -$87.4M | -$11.9M | $27.6M | $5.9M |
| Diluted EPS | -$0.26 | -$0.32 | -$0.34 | -$0.04 | $0.10 | $0.02 |
| Operating cash flow | -$28.1M | -$61.7M | -$80.7M | $34.1M | $42.5M | $18.3M |
| Free cash flow | -$28.9M | -$73.2M | -$88.3M | -$8.3M | $32.8M | $13.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -73.5% | -62.3% | -64.3% | 4.4% | 25.4% | 11.1% |
| Net margin | -87.9% | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.4M | $70.1M | $76.8M | $78.4M | $76.5M | $82.1M | $112.0M | $90.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $16.6M | $12.8M | $26.5M | $22.3M | $5.3M | $18.9M | -$7.7M | -$1.7M |
| Net income | -$2.0M | $11.6M | $7.4M | $13.2M | $668,000.00 | $8.0M | -$15.9M | -$16.6M |
| Diluted EPS | -$0.01 | $0.04 | $0.03 | $0.04 | $0.00 | $0.03 | -$0.05 | -$0.05 |
| Operating cash flow | $3.8M | $9.3M | $22.6M | -$6.4M | $8.9M | $23.6M | -$8.0M | -$5.4M |
| Free cash flow | $861,000.00 | $7.9M | $19.7M | -$6.7M | $7.8M | $22.5M | -$10.0M | -$7.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 22.9% | 18.2% | 34.5% | 28.5% | 6.9% | 23.0% | -6.9% | -1.8% |
| Net margin | -2.8% | 16.5% | 9.7% | 16.8% | 0.9% | 9.7% | -14.2% | -18.4% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-17 | Binder Steven B. | Sale | 52,485 | $4.06 | $213,089.10 | filing |
| 2026-07-17 | Thomson David· EVP Genl Counsel & Secretary | Sale | 24,109 | $4.05 | $97,641.45 | filing |
| 2026-07-15 | Castagna Michael· Chief Executive Officer | Tax withholding | 192,819 | $4.09 | $788,629.71 | filing |
| 2026-07-15 | Castagna Michael· Chief Executive Officer | Tax withholding | 63,996 | $4.09 | $261,743.64 | filing |
| 2026-07-15 | Castagna Michael· Chief Executive Officer | Tax withholding | 58,904 | $4.09 | $240,917.36 | filing |
| 2026-07-15 | Thomson David· EVP Genl Counsel & Secretary | Tax withholding | 51,632 | $4.09 | $211,174.88 | filing |
| 2026-07-15 | Castagna Michael· Chief Executive Officer | Tax withholding | 47,481 | $4.09 | $194,197.29 | filing |
| 2026-07-15 | Tross Stuart A· Chief People & Workpl Officer | Tax withholding | 33,652 | $4.09 | $137,636.68 | filing |
| 2026-07-15 | Singh Sanjay R· EVP Technical Operations | Tax withholding | 22,047 | $4.09 | $90,172.23 | filing |
| 2026-07-15 | Thomson David· EVP Genl Counsel & Secretary | Tax withholding | 17,754 | $4.09 | $72,613.86 | filing |
| 2026-07-15 | Thomson David· EVP Genl Counsel & Secretary | Tax withholding | 16,378 | $4.09 | $66,986.02 | filing |
| 2026-07-15 | Binder Steven B. | Tax withholding | 15,688 | $4.09 | $64,163.92 | filing |
| 2026-07-15 | Thomson David· EVP Genl Counsel & Secretary | Tax withholding | 12,662 | $4.09 | $51,787.58 | filing |
| 2026-07-15 | Tross Stuart A· Chief People & Workpl Officer | Tax withholding | 12,331 | $4.09 | $50,433.79 | filing |
| 2026-07-15 | Prentiss Christopher B· Chief Financial Officer | Tax withholding | 11,572 | $4.09 | $47,329.48 | filing |
| 2026-07-15 | Tross Stuart A· Chief People & Workpl Officer | Tax withholding | 11,572 | $4.09 | $47,329.48 | filing |
| 2026-07-15 | Prentiss Christopher B· Chief Financial Officer | Tax withholding | 10,675 | $4.09 | $43,660.75 | filing |
| 2026-07-15 | Singh Sanjay R· EVP Technical Operations | Tax withholding | 10,079 | $4.09 | $41,223.11 | filing |
| 2026-07-15 | Singh Sanjay R· EVP Technical Operations | Tax withholding | 9,297 | $4.09 | $38,024.73 | filing |
| 2026-07-15 | Tross Stuart A· Chief People & Workpl Officer | Tax withholding | 8,253 | $4.09 | $33,754.77 | filing |
| 2026-07-15 | Singh Sanjay R· EVP Technical Operations | Tax withholding | 5,372 | $4.09 | $21,971.48 | filing |
| 2026-07-15 | Binder Steven B. | Tax withholding | 4,634 | $4.09 | $18,953.06 | filing |
| 2026-07-15 | Binder Steven B. | Tax withholding | 4,073 | $4.09 | $16,658.57 | filing |
| 2026-07-15 | Marasco Dominic· Pres, Endocrine Business Unit | Tax withholding | 3,623 | $4.09 | $14,818.07 | filing |
| 2026-07-15 | Thomson David· EVP Genl Counsel & Secretary | Option exercise | 93,790 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.